

# Seroprotection of Hepatitis B Vaccine and Need for Booster Dose: A Meta-Analysis

Jalal Poorolajal <sup>1\*</sup>, Mahmood Mahmoodi <sup>1</sup>, Reza Majdzadeh <sup>1</sup>, Siavosh Nasseri-Moghaddam <sup>2</sup>, AliAkbar Haghdoost <sup>3</sup>, Leila Ghalichi <sup>1</sup>, Akbar Fotouhi <sup>1</sup>

<sup>1</sup> Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran

<sup>2</sup> Digestive Disease Research Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran

<sup>3</sup> Community Medicine Department and Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran

*Background and Aims:* The duration of protection provided by hepatitis B (HB) vaccine is still unknown but can be estimated indirectly by measuring the anamnestic immune response to booster doses of the vaccine.

*Methods:* We searched electronic databases and conference databases up to December 2008. We also screened reference lists of articles and contacted the authors and vaccine manufacturers for additional references. We included randomized and nonrandomized studies assessing the anamnestic immune response to the booster of HB vaccine in healthy participants 5 years or more after initial vaccination.

*Results:* The meta-analysis included 34 studies with 53 intervention groups and 4,479 individuals. The protective antibodies induced by initial vaccination waned over time; however, nonprotected vaccinees who had lost their antibodies to hepatitis B surface antigen (anti-HBs) over time responded strongly to the booster dose. The seroprotection rate of HB vaccine after the primary vaccination was 98.00% [95% confidence interval (CI): 95.32%, 99.52%] after 5 years, 96.88% [95% CI: 94.61%, 98.50%] after 6-10 years, 88.80% [95% CI: 79.84%, 95.08%] after 11-15 years, and 85.12% [95% CI: 82.18%, 88.20%] after 16-20 years.

*Conclusions:* According to these findings, the protection provided by HB vaccine is dependent on immune memory rather than anti-HBs titer; therefore, recommendations for booster doses should be based on immune memory instead of the persistence of antibody. In addition, a full course of HB vaccination can induce a long-term and strong serologic immunity against hepatitis B virus infection. Nonetheless, the decreasing trend of seroprotection during the first and second decades after immunization indicates that the long-term immunity induced by HB vaccine may diminish over time. This issue raises the possibility of the need for a booster dose, although universal revaccination does not seem necessary during the first and second decades after primary vaccination in healthy individuals with normal immune status who had fully responded to a complete course of the vaccine.

Keywords: Hepatitis B Vaccine, Immunization, Immunologic Memory, Immunity

## Introduction

The protection provided by hepatitis B (HB) vaccine has been well documented  $^{(1, 2)}$ . Antibody to hepatitis B surface antigen (anti-HBs) concentrations  $\geq 10$  mIU/ml are generally considered protective against hepatitis B virus (HBV) infection  $^{(1, 3)}$ . However, the protective antibodies induced by HB vaccination wane gradually over time and may reach very low or even undetectable levels  $^{(4, 5)}$ .

Some long-term follow-up studies have indicated that a 3-dose vaccination schedule provides immunity

\* Correspondence: Jalal Poorolaial. M.D.

Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran.

Tel/Fax: +98 21 6642 1746

E-mail: poorolajal@umsha.ac.ir

**Received:** 17 Jun 2009 **Accepted:** 29 Sep 2009 **Revised:** 18 Aug 2009

Hepat Mon 2009; 9 (4): 293-304

against HBV infection for as long as 15 years  $^{(2, 6)}$ . In addition, immunologic studies have revealed that HB vaccine induces immunologic memory, so that memory B cells can proliferate, differentiate, and retain the capacity to generate a rapid and vigorous anamnestic immune response upon re-exposure to hepatitis B surface antigen (HBsAg), even if the anti-HBs titer falls below the protective level (7-9). Hence, disappearance of the antibody does not necessarily imply loss of protection. Nonetheless, HBV breakthrough infection and chronic carriage state have been reported in some vaccinees especially in endemic regions (2, 6, 10). Moreover, adults are less likely than infants to demonstrate an anamnestic response as they grow older <sup>(7)</sup>, and the risk of HBV infection increases with sexual and occupational exposure during adulthood <sup>(11)</sup>. In the context of these relatively limited results, the duration of immunity provided by the complete course of the vaccine is unknown because vaccine protection is not parallel to anti-HB titer. Indeed, it is not clear whether a decline in serum anti-HB level indicates the need for a booster dose.

There is a practical approach to determining the duration of protection provided by HB vaccine. In this approach, we assumed that the response to the booster dose mimics the response to the wild virus. Therefore, through measuring the immune response after administration of a booster dose of the vaccine at definite time intervals from the initial vaccination, we indirectly assessed the presence of anamnestic immune response (AIR) and therefore the vaccine's long-term immunogenicity against HBV infection.

Because unnecessary HB revaccination is wasteful, none of the international guidelines recommend that booster doses be administered universally <sup>(1, 12-14)</sup>. Furthermore, the duration of protection provided by HB vaccine is important for public health authorities who have to plan immunization programs and formulate future booster policies. As a result, the seroprotection rate of HB vaccine still requires further investigation <sup>(12, 15, 16)</sup>. We found a few review articles <sup>(1, 15-17)</sup> but no metaanalysis addressing the booster dose of HB vaccine. In this meta-analysis, we took a practical approach to determine the "seroprotection rate" (SR) of HB vaccine and the need for a booster dose.

#### **Materials and Methods**

AIR is typically defined in two ways <sup>(8, 9, 18, 19)</sup>: a) experiencing a four-fold or greater rise in post-booster anti-HBs titer within 2 to 4 weeks of the booster dose administration for participants having detectable antibody or b) developing a post-booster anti-HBs level equal to or greater than 10 mIU/ml within 2 to 4 weeks of the booster dose administration for participants with no detectable antibody. In addition, protected participants are defined as vaccinees having an anti-HBs titer <10 mIU/ml, and nonprotected participants are defined as vaccinees having an anti-HBs titer <10 mIU/ml (1, 3).

#### Criteria for including studies

Types of studies: Both randomized and nonrandomized studies addressing AIR to booster doses of vaccines were included in this meta-analysis. We considered nonrandomized studies, because most studies exploring immune response to booster dose were nonrandomized in design (Fig. 1). We included studies irrespective of randomization, publication status, or language. We excluded short-



# Figure 1. Design of the review for assessing the long-term seroprotection of HB vaccine

P1: proportion of protected participants;

P2: proportion of nonprotected participants;

P<sub>AIR</sub>: proportion of anamnestic immune response in nonprotected participants.

term trials (fewer than 5 years follow-up from the initial vaccination).

participants: We limited our Types of investigation to apparently healthy participants, who had intact immune status, no previous HBV infection, and who had already received a complete course of HB vaccine. We excluded those studies whose participants a) were not screened for serologic markers of HBV infection before admission to the study; b) were born to carrier mothers; c) had no clear and reliable vaccination history; d) received an incomplete course of HB vaccine; e) received HB vaccine in fixed combination with other vaccines; f) received HB vaccine plus immunoglobulin; and g) had predisposing factors for immunodeficiency such as HIV or hemodialysis.

**Types of intervention:** The intervention of interest was administering a booster dose of HB vaccine to already immunized participants to assess the longterm presence (5 years or more) of AIR to the booster dose (Fig. 1). We assessed booster effect irrespective of type, dosage, injection route, and injection site.

**Types of primary outcomes:** We assessed two types of primary outcomes, including a) the proportion of protected participants at the end of the follow-up period (P) and b) the proportion of nonprotected participants with AIR to the booster dose ( $P_{AID}$ ).

### Search methods

Electronic databases: We searched the Cochrane Hepato-Biliary Group Controlled Trials Register (2008), the Cochrane Central Register of Controlled Trials (*The Cochrane Library* 2008, Issue 3), MEDLINE (Jan 1950 to Dec 2008), EMBASE (Jan 1980 to Dec 2008), and Science Citation Index Expanded (Jan 1945 to Dec 2008).

Other sources: We scanned the reference lists of all included studies for additional references. We also contacted the authors of the included studies as well as vaccine manufacturers for additional unpublished trials. In addition, the following conference databases were searched for unpublished data:

- Annual Meeting of the Infectious Diseases Society of America (IDSA), retrieved from *htttp://www. idsociety.org*;
- European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), retrieved from *http://www.escmid.org*; and
- Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) retrieved from *http://www.icaac.org*.

## Data collection and analysis

Two authors independently made the decisions on which trials meet the inclusion criteria considered for this review. The two authors were not blinded to the names of the authors of the included studies, the journals, or the results. Any disagreements were resolved through discussion among the authors until a consensus was reached. Excluded trials were listed with the reasons for exclusion.

We extracted data regarding the Data Collection and Abstraction Form. In cases of missing data or need for clarification, the trial authors were contacted.

Three authors assessed the risk of bias in the included studies using a risk-of-bias tool. Any disagreements were resolved through discussion among the authors until a consensus was reached. The studies that had an adequate handling of incomplete outcome data, were free of selective reporting, included an adequate intervention description, had appropriate criteria for participant recruitment, and included an adequate outcome explanation were considered low-bias risk trials. The studies with one or more unclear or inadequate quality component were considered high-bias risk trials.

To handle withdrawals and dropouts in the analysis, we used an available-participant approach, meaning that we included data on only those participants whose results were known, using as a denominator the total number of people who had data recorded for AIR.

### Seroprotection rate

Vaccinated individuals having an anti-HBs level ≥10 mIU/ml are generally considered protected <sup>(1, 3)</sup>, whereas vaccinated people with an anti-HBs level <10 mIU/ml may not be protected and are assessed in this review. Seroprotection rate (SR) determines the proportion of protective immunity provided by HB vaccine among vaccinated individuals. SR consists of the proportion of protected participants plus the proportion of nonprotected participants who responded to the booster. SR is calculated by the following formula <sup>(20)</sup>:

 $SR = [P_1 + (P_2 \times P_{AIR})] \times 100,$ 

where  $P_1$  is proportion of protected participants;  $P_2$  is proportion of nonprotected participants; and  $P_{AIR}$  is the proportion of nonprotected participants with an anamnestic immune response. Both Review Manager 5 <sup>(21)</sup> and Stata 9 were used

Both Review Manager 5 <sup>(21)</sup> and Stata 9 were used for the data analysis. A meta-analysis was performed to obtain the summary measures P<sub>2</sub> and P<sub>AIR</sub> using a random-effects model with a 95% confidence interval (CI). To explore statistical heterogeneity we used the chi-square ( $\chi^2$  or Chi<sup>2</sup>) test at the 10% significance level (P < 0.10). We also used the I<sup>2</sup> statistic to quantify inconsistency in results across studies. In addition, a funnel plot was employed for assessing publication bias.

### **Results**

#### Description of studies

We retrieved 4,699 studies up to December 2008, including 2,208 studies by searching electronic databases, 2,467 studies by checking reference lists, and 24 studies through personal contact with study authors or searching conference databases. Of the 46 studies considered potentially eligible after screening, 34 (7-9, 18, 20, 22-50) were eventually included in the review and 12 studies were excluded <sup>(51-62)</sup>.

Of the 34 included studies, 33 studies <sup>(7-9, 18, 20, 22-34, 36-50)</sup> were published in English, and one study was written in Chinese <sup>(35)</sup>. Thirty-three studies were published as full papers, and one study <sup>(45)</sup> was a poster presentation. All included studies were either randomized or nonrandomized in design. Randomized clinical trials included multiple parallel intervention groups without a control group. These parallel intervention groups varied by booster dosage, route or site of injection, vaccination schedule, age, and so on. Hence, there were 34 studies having 53 intervention groups overall. We considered each intervention group as a separate study for analysis.

There were 15 low-risk trials among the included studies, and the remaining 19 trials were high risk. Overall, adequate handling of incomplete outcome data was 88.2%. About 76.5% of the included trials were free of selective reporting. The intervention was well defined in all but one (97%) of the studies. The eligibility criteria for selection and recruitment of participants were addressed clearly in 79.4% of the trials. The definition of AIR was mentioned clearly in 55.9% of the included trials (Fig. 2).

#### Intervention effects

This meta-analysis included 34 studies with 53 intervention groups and 4,479 participants. The 53 intervention groups were divided into four different strata based on the duration of the last vaccination (Table 1). Stratum 1 included studies that assessed AIR to booster dose 5 years after the initial vaccination; Stratum 2 included studies that assessed AIR to booster dose 6 to 10 years after the initial vaccination; Stratum 3 included studies that assessed AIR to booster dose 11 to 15 years after the initial vaccination; and Stratum 4 included studies that assessed AIR to booster dose 16 to 20 years after the initial vaccination. Stratum 1 included 12 intervention groups with 480 participants; Stratum 2 included 27 intervention groups with 1,405 participants; Stratum 3 included 12 intervention groups with 1,883 participants; and Stratum 4 included 2 intervention groups with 711 participants.

The proportion of protected participants ( $P_1$ ) was the complement of the proportion of nonprotected participants ( $P_2$ ), and therefore  $P_1$  (Fig. 3) decreased over time as  $P_2$  increased. Furthermore, the proportion of AIR to the booster dose ( $P_{AIR}$ ) (Fig. 4) and SR decreased, albeit more slowly over time (Fig. 5).

Because the follow-up period from booster injection to blood sampling was short (between 1 to 4 weeks), the amount of missing participants due to dropout was negligible (37 out of 4,479 participants).

We assessed reporting bias using the funnel plot, which was asymmetric for both  $P_2$  and  $P_{AIR}$ . The Chi<sup>2</sup> test for heterogeneity was large, and thus the P value was low in all strata (P < 0.001), indicating that there was heterogeneity in the results across studies. The I<sup>2</sup> statistic also confirmed heterogeneity. To explore the reasons for heterogeneity across studies, we divided the data into subgroups according to the different variables under investigation and then performed the meta-analysis across subgroups.



**Figure 2.** Methodological quality graph: review authors' judgments about each methodological quality item, presented as percentages across all included studies.

	Table	I. Summary of			u studies	ſ	Ĩ	1
Trial	Follow-up	Participants	Vaccine	MA (yr)	Ν	P <sub>1</sub>	P <sub>2</sub>	P <sub>AIR</sub>
Belloni 2000 (22)	5	GP	RV	5	51	0.71	0.29	1
Da Villa 1996 (23)	5	GP	Mixed	5	27	0.93	0.07	0.96
Dahifar 2008 (24)	5	GP	RV	6.5	4	0.94	0.06	1
Gilca 2008 (25)	5	GP	RV	15.5	36	0.87	0.13	0.94
Milne 1992a (26)	5	GP	PDV	6.1	55	0.83	0.17	0.82
Petersen 2004 (27)	5	GP	RV	5.2	71	0.13	0.87	0.85
Williams 2003 (18)	5	GP	RV	5.3	44	0.37	0.63	0.93
Duval 2005 (28)	5	GP	RV	15.1	38	0.87	0.13	0.92
Duval 2005 (28)	5	GP	RV	15.1	50	0.82	0.18	0.96
Milne 1992b (29)	5	GP	RV	18	8	0.89	0.11	1
Bucher 1994 (30)	5	HCWs	PDV	40.9	49	0.83	0.17	0.80
Bucher 1994 (30)	5	HCWs	PDV	40.4	47	*	*	0.89
Li 1998 <sup>(31)</sup>	6	GP	PDV	6-7	65	0.55	0.45	0.77
Samandari 2007 (7)	6	GP	RV	5.9	116	0.29	0.71	0.97
Seto 2002 (32)	6	GP	RV	6.1	34	0.19	0.81	1
Floreani 2004 (33)	6	HCWs	PDV	28.8	7	0.90	0.10	1
Floreani 2004 (33)	6	HCWs	RV	31.4	11	0.68	0.32	0.45
Trivello 1995 (34)	6	HCWs	PDV	30.8	99	0.67	0.33	0.92
Trivello 1995 (34)	6	HCWs	PDV	29.8	40	0.94	0.06	0.88
Li 1996 <sup>(35)</sup>	7	GP	PDV	8-11	26	0.51	0.34	1
Petersen 2004 (27)	7	GP	RV	75	14	*	*	1
Petersen 2004 (27)	7	GP	RV	7.5	21	0	1	0.86
Davidson 1986 (36)	7	HCWs	PDV	43	16	0.48	0.52	0.81
Davidson 1980	8	CP	RV RV	81	63	*	*	0.01
Milne 199/ <sup>(37)</sup>	9	CP	RV	11.12	17	0.86	0.1/	0.9/
Petersen 200/ <sup>(27)</sup>	9	CP	PDV	9.1	25	*	*	0.54
W/illiama 2002 (18)	9	CP	PDV	9.1	25	0.20	0.61	0.92
Williams 2001 <sup>(38)</sup>	9	HCWe	PV	9.2)	13	*	*	1
Williams 2001 (38)	9	HCWs	PV	46.7	15	0.74	0.26	1
De Ville 1996 <sup>(23)</sup>	10	CP		10	1/7	0.74	0.20	0.96
Da villa 1990	10	CP	PDV	10 /	20	0.09	0.51	0.90
Soffar 2004 (39)	10	CP		10.4	52	*	*	0.09
Saffar 2004 (39)	10	CP	RV DV	10.7	57	0.58	0.42	0.00
Saffar 2004 (39)	10	CP	RV DV	10.7	56	*	*	0.93
7	10	Gr	RV DV	10.7	242	0.6	0.26	0.79
Cilar 2009 (25)	10	GP	RV	10.9	62	0.04	0.50	0.97
Glica 2008 (40)	10	GP	RV	20.5	42	0.85	0.15	
Chadha 2000 (4)	10		RV	21.8	40	0.89	0.11	0.90
Chadna 2000 (42)	10		RV DV	3/.3	10	0.19	0.81	0.8
Durlach 2005 (*)	10		RV DV	44.5	1)	0.8/	0.15	0.02
Gabbuti 2007 (44)	11	GP		25	12	0.91	0.09	0.92
Deterror 2004 (27)	11	GP	PDV	10-20	12	0.24	0.7(	0./8
Server der: 2007 (7)	12	GP	PDV	12.0	12	0.24	0.76	0.07
Samandari 2007 (7)	12	GP	RV	11.8	522	0.14	0.86	0.81
Lu 2008a (4))	13	GP	RV	13-14	522	0.31	0.69	0./4
Watson 2001 <sup>(9)</sup>	13	GP	RV	14-23	3	0.83	0.1/	1
Watson 2001 (9)	13	GP	RV	43-6/	2	0./1	0.29	1
Samandari 2007 (/)	14	GP	PDV	14	58	0.22	0./8	0.60
Hammitt 2007 (46)	15	GP	RV	14.6	37	*	*	0.62
LU 2004 (4/)	15	GP	PDV	15	68	0.38	0.62	0.96
Lu 2008b <sup>(48)</sup>	15	GP	PDV	15-17	872	0.37	0.63	0.71
van der Sande 2007 <sup>(8)</sup>	15	GP	PDV	14.9	148	0.34	0.66	0.95
Wang 2007 (20)	16	GP	PDV	15.9	395	*	*	0.77
Su 2007 (49)	20	GP	PDV	18.7	316	0.38	0.62	0.75

Table 1 Summary of results from the included studies

 P1: proportion of protected participants
 N: sample size
 MA: mean age

 P2: proportion of nonprotected participants
 RV: recombinant vaccine
 GP: general population

 PAIR: proportion of anamnestic immune response
 PDV: plasma derived vaccine
 HCWs: health care workers

 \* In these studies, the booster dose was administered to nonprotected participants, but the proportion with protected and nonprotected participants was not specified.

Study or Subgroup 1.1.1 Stratum 1 Belloni 2000 Bucher 1994 Da Villa 1996	PNV	SE	Total	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
<b>1.1.1 Stratum 1</b> Belloni 2000 Bucher 1994 Da Villa 1996	0.20						
Belloni 2000 Bucher 1994 Da Villa 1996	0.20						
Bucher 1994 Da Villa 1996	0.29	0.0320858	200	0	9.1%	0.29 [0.23, 0.35]	-
Da Villa 1996	0.1716814	0.0158649	565	0	9.2%	0.17 [0.14, 0.20]	-
	0.0708661	0.0131461	381	0	9.2%	0.07 [0.05, 0.10]	-
Dahifar 2008	0.0588235	0.0285336	68	0	9.1%	0.06 0.00 0.111	-
Duval 2005	0 1838235	0.0234859	272	ň	0.1%	0.18 [0.14, 0.23]	+
Duval 2005	0.1030233	0.0234635	272		0.1%	0.10 [0.14, 0.23]	-
Duval 2005	0.1262458	0.0191434	301	0	9.1%	0.13 [0.09, 0.16]	
Gilca 2008	0.1272085	0.0198071	283	0	9.1%	0.13 [0.09, 0.17]	-
Milne 1992a	0.172956	0.0212089	318	0	9.1%	0.17 [0.13, 0.21]	-
Milne 1992b	0.1126761	0.0375256	71	0	9.0%	0.11 [0.04, 0.19]	
Petersen 2004	0.875	0.0229312	208	0	9.1%	0.88 [0.83, 0.92]	-
Williams 2003	0.6285715	0.0577519	70	0	8.8%	0.63 [0.52, 0.74]	
Subtotal (95% CI)	0.02001.00		2737	ŏ	100.0%	0.25 [0.12, 0.39]	•
Heterogeneity Tau <sup>2</sup> = (	0.05 <sup>,</sup> Chi <sup>2</sup> = 10	99.22 df = 10	(P < 0.00	11) 17 =	00%	• • •	-
Test for overall effect: 2	Z = 3.69 (P = 0.1)	0002)	(1 - 0.00	,,,, -	3370		
		,					
1.1.2 Stratum 2	c			-			
Chadha 2000	0.8125	0.0975781	16	0	4.2%	0.81 [0.62, 1.00]	
Da Villa 1996	0.312766	0.0213852	470	0	4.7%	0.31 [0.27, 0.35]	-4
Davidson 1986	0.51612902	0.0897559	31	0	4.2%	0.52 [0.34, 0.69]	
Durlach 2003	0.131579	0.0316596	114	0	4.6%	0.13 [0.07, 0.19]	-
Floreani 2004	0.0958904	0.0344617	73	0	4.6%	0.10 [0.03, 0.16]	
Floreani 2004	0.3235204	0.0803300	34	0	4 296	0.32 [0.17 0.49]	
Gilco 2009	0.5235234	0.0002308	34		4.370	0.02 [0.17, 0.40]	
01108 2000	0.1521739	0.0210207	270	0	4.770	0.15[0.11, 0.19]	
LI 1990	0.3391813	0.0362042	171	U	4.0%	0.34 [0.27, 0.41]	
LI 1998	0.4513889	0.0414693	144	0	4.6%	0.45 [0.37, 0.53]	
Milne 1994	0.136	0.0306599	125	0	4.6%	0.14 [0.08, 0.20]	-
Peces 2001	0.2173913	0.0608155	46	0	4.5%	0.22 [0.10, 0.34]	<b></b> -
Petersen 2004	0.5882353	0.0487304	102	0	4.5%	0.59 [0.49, 0.68]	
Petersen 2004	1	0.0344601	36	0	4.6%	1.00 (0.93, 1.07)	
Saffar 2004	0.4216335	0.0232017	453	ň	4.6%	0 42 0 38 0 471	-
Comondori 2007	0.4210333	0.0252017	400		4.0 %	0.42 [0.30, 0.47]	-
Samanuan 2007	0.7108434	0.0351884	100	0	4.0%	0.71 [0.64, 0.78]	
Seto 2002	0.8095238	0.0605913	42	0	4.5%	0.81 [0.69, 0.93]	
Trivello 1995	0.3278146	0.0270119	302	0	4.6%	0.33 [0.27, 0.38]	-
Trivello 1995	0.0612557	0.0093841	653	0	4.7%	0.06 [0.04, 0.08]	-
Williams 2001	0.2616822	0.042493	107	0	4.6%	0.26 [0.18, 0.34]	
Williams 2003	0.6097561	0.0761823	41	0	4 4 %	0.61 (0.46, 0.76)	
Zanatti 2005	0.1076233	0.0146744	446	ň	1 7%	0.11 [0.08 0.14]	
Zanetti 2005	0.2672607	0.0107644	1010		4.7 %	0.11 [0.00, 0.14]	
Subtotal (05% CI)	0.3572607	0.0137644	5060	0	4.7 %	0.30 [0.33, 0.36]	
Johorogeneity Teuz - (	0.05: 05: - 15	60 4 A AF - 04	(D < 0.0)	143112-	0.0%	0.59 [0.50, 0.49]	•
Heterogeneity: Taur = t Test for overall effect: 7	0.05; Cnr = 15 7 = 8 11 (P < 0	63.14, af = 21 NNNN1)	(P < 0.00	J1); I*=	99%		
		,					
1.1.3 Stratum 3				-			
Gabbuti 2007	0.0877193	0.0187346	228	0	10.6%	0.09 [0.05, 0.12]	*
Lu 2004	0.6238532	0.0463988	109	0	10.3%	0.62 [0.53, 0.71]	
Lu 2008a	0.6862276	0.0160583	835	0	10.6%	0.69 [0.65, 0.72]	•
Lu 2008b	0.629995	0.0062429	5981	0	10.6%	0.63 [0.62, 0.64]	
Petersen 2004	0.7647059	0.1028794	17	0	9.3%	0.76 (0.56, 0.97)	
Samandari 2007	0.7827929	0.0479549	7.4	ő	10.2%	0 78 0 60 0 001	
Comondori 2007	0.00000000	0.0470048	400		10.370	0.00 [0.00, 0.00]	
Samandan 2007	0.8623188	0.0293313	138	U	10.5%	0.86 [0.80, 0.92]	<b>~</b>
van der Sande 2007	0.6577778	0.0316302	225	U	10.5%	0.66 [0.60, 0.72]	
Watson 2001	0.2857143	0.170747	7	0	7.7%	0.29 [-0.05, 0.62]	+- <b>-</b>
Watson 2001	0.1666667	0.087841	18	0	9.6%	0.17 [-0.01, 0.34]	<b>⊢−</b> ,
Subtotal (95% CI)			7632	0	<b>100.0</b> %	0.56 [0.41, 0.72]	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: 2	0.06; Chi² = 92 Z = 7.29 (P < 0.	8.18, df = 9 (F 00001)	° < 0.001)	; I² = 99	1%		
		,					
1.1.4 Stratum 4	0.0003377	0.0400000			100.00	0.0010 00.000	
Su 2007 Subtotal (05% Ch	0.6227758	0.0166937	843	0	100.0%	0.62 [0.59, 0.66]	
Subtotal (95% CI)			843	U	100.0%	0.02 [0.59, 0.66]	•
Heterogeneity: Not app	olicable						
Test for overall effect: Z	Z = 37.31 (P < (	J.001)					

Figure 3. Forest plot of proportion of nonprotected participants (PNP) across different strata.

		E	looster			AIR	A	IR
Study or Subgroup	AIR	SE	Total	Total	Weight	IV, Random, 95% Cl	IV, Rando	m, 95% Cl
1.2.1 Stratum 1	4	0.0050444	51		10.10	1 00 00 05 1 051		-
Bellofil 2000 Bucher 1994	1	0.0252411	51	0	10.1%	1.00 [0.95, 1.05] 0.89 [0.81 - 0.98]		L -
Bucher 1994	0.7959183	0.0575756	49	Ő	8.1%	0.80 [0.68, 0.91]		
Da Villa 1996	0.962963	0.0363447	27	0	9.5%	0.96 [0.89, 1.03]		4-
Dahifar 2008	1	0.1530931	4	0	3.2%	1.00 [0.70, 1.30]		<b>_</b>
Duval 2005	0.9210526	0.0437441	38	0	9.0%	0.92 [0.84, 1.01]		
Duval 2005 Gileo 2009	0.96	0.0277128	50	0	9.9%	0.96 [0.91, 1.01]		-
Milne 1992a	0.9444444	0.0381769	30 55	0	9.4%	0.94 [0.87, 1.02] 0.82 [0.72, 0.92]		
Milne 1992b	1	0.1075829	8	Ő	5.0%	1.00 [0.79, 1.21]		
Petersen 2004	0.8450704	0.0429422	71	0	9.1%	0.85 [0.76, 0.93]		
Williams 2003	0.9318182	0.0379991	44	0	9.4%	0.93 [0.86, 1.01]		<b>—</b>
Subtotal (95% CI)	0.00: Chi <b>Z</b> – 2/	1 06 df - 11 /D	400 - 0.010\:	U 12 - 66	100.0%	0.92 [0.88, 0.90]		•
Test for overall effect: 2	Z = 48.64 (P <	0.00001)	- 0.010),	, 1 - 50	.,0			
		,						
1.2.2 Stratum 2								
Chadha 2000	0.8	0.1264911	10	0	2.0%	0.80 [0.55, 1.05]		
Da Villa 1996 Davideon 1996	0.9591837	0.0163196	147	0	4.9%	0.96 [0.93, 0.99]		
Durlach 2003	0.0123	0.1032796	15	0	2.5%			
Floreani 2004	1	0.1162913	7	Ō	2.2%	1.00 [0.77, 1.23]		_ <b></b>
Floreani 2004	0.4545455	0.1501314	11	0	1.6%	0.45 [0.16, 0.75]		
Gilca 2008	1	0.030068	42	0	4.7%	1.00 [0.94, 1.06]		+
Li 1996	1	0.045542	26	0	4.2%	1.00 [0.91, 1.09]		
LI 1998 Milne 1994	0.7692308	0.0522589	05 17	0	4.0%	0.77 [0.67, 0.87] 0.94 [0.83, 1.05]		
Petersen 2004	1	0.0740741	14	Ő	3.3%	1.00 [0.85, 1.15]		
Petersen 2004	0.952381	0.0268303	63	Ō	4.7%	0.95 [0.90, 1.00]		+
Petersen 2004	0.6896552	0.0859091	29	0	2.9%	0.69 [0.52, 0.86]		
Petersen 2004	0.52	0.09992	25	0	2.6%	0.52 [0.32, 0.72]		
Petersen 2004 Soffor 2004	0.85/1429	0.0763604	21	0	3.2%	0.86 [0.71, 1.01] 0.70 (0.60, 0.00)		
Saffar 2004	0.7857145	0.0546521	52	0	3.970 4.7%	0.79 [0.00, 0.09] 0.88 [0.80, 0.97]		
Saffar 2004	0.9473684	0.0295764	57	Ō	4.7%	0.95 [0.89, 1.01]		-
Samandari 2007	0.9741379	0.0147371	116	0	5.0%	0.97 [0.95, 1.00]		•
Seto 2002	1	0.0362235	34	0	4.5%	1.00 [0.93, 1.07]		+
Trivello 1995	0.875	0.0522913	40	0	4.0%	0.88 [0.77, 0.98]		-
Milliams 2001	0.9191919	0.0273913	99 13	0	4.770	0.92 [0.87, 0.97] 1.00 [0.85, 1.15]		
Williams 2001	1	0.0704059	15	Ő	3.4%	1.00 [0.86, 1.14]		
Williams 2003	0.88	0.0649923	25	0	3.6%	0.88 [0.75, 1.01]		
Zanetti 2005	0.9583333	0.0288425	48	0	4.7%	0.96 [0.90, 1.01]		+-
Zanetti 2005 Subtotal (05% CI)	0.9707602	0.0091102	342	0	5.0%	0.97 [0.95, 0.99]		
Heterogeneity: Tau <sup>2</sup> =	0.00° Chiž = 89	312 df= 26/P	< 0.001)	1² = 70	100.0%	0.92 [0.69, 0.95]		,
Test for overall effect: 2	Z = 66.74 (P ≺	0.00001)	~ 0.001),	, 1 - 70				
		,						
1.2.3 Stratum 3						0 00 K == · · · ·		_
Gabbuti 2007	0.9166667	0.0797856	12	0	7.6%	0.92 [0.76, 1.07]		
Hammitt 2007	0.6216216 0.0501937	0.07973066	37 68	0	7.6% 11.4%	0.62 [0.47, 0.78] 0.96 [0.90, 1.01]		
Lu 2004 Lu 2008a	0.7413793	0.0191653	522	0	11.9%	0.74 [0.70, 0.78]		
Lu 2008b	0.7075688	0.0154042	872	Ō	12.0%	0.71 [0.68, 0.74]		-
Petersen 2004	0.6666667	0.1360828	12	0	4.4%	0.67 [0.40, 0.93]		
Samandari 2007	0.8050848	0.0364672	118	0	10.9%	0.81 [0.73, 0.88]		
Samandari 2007	0.6034483	0.0642327	58	0	8.8%	0.60 [0.48, 0.73]		
Watson 2001	0.331043	0.0100432	140	0	3.2%	1.00 [0.67, 1.33]		
Watson 2001	1	0.1924501	2	0	2.7%	1.00 [0.62, 1.38]		<b>_</b>
Xueliang 2000	0.7777778	0.0800091	31	0	7.6%	0.78 [0.62, 0.93]		
Subtotal (95% CI)	0.00.01.7.4/		1883	0	100.0%	0.80 [0.72, 0.88]		•
Heterogeneity: Tau* = Test for overall effect: 2	0.02; Chi≝ = 18 Z = 19.05 (P ≺	0.00001)	r < 0.001	); i*= 9	15%0			
1.2.4 Stratum 4								
Su 2007	0.7531645	0.0242552	316	0	49.7%	0.75 [0.71, 0.80]		
Wang 2007	0.7720207	0.0213535	395	0	50.3%	0.77 [0.73, 0.81]		
Subtotal (95% CI)	0.00-058-0	04 df = 4 (D -	711	0	100.0%	0.76 [0.73, 0.80]		•
Test for overall effect: 1	0.00; Cni* = 0. 7 = 47.65 (P <	34, 01 = 1 (P = 1 0 00001)	u.50); (*=	0%				
. cottor overall ellett. 2	2 . 41.00 (1 . 5	0.00001)						
							-1 -0.5 (	
						Fa	avours experimental	Favours control

Figure 4. Forest plot of anamnestic immune response (AIR) to booster dose in nonprotected participants across different strata.



Figure 5. Proportion of protected and nonprotected participants, proportion of anamnestic immune response to booster dose among nonprotected participants, and the seroprotection rate of HB vaccine in different periods after primary vaccination.

### Subgroup analysis

To assess the effect of various variables on the seroprotection rate of HB vaccine, we ignored the strata and performed the subgroup analysis of all studies together to enhance sample sizes across different levels of variables to obtain more precise estimates. The variables under investigation included the methodological quality of the studies, types of participants, and types of vaccine.

There were 15 low-risk and 19 high-risk trials among the included studies. The subgroup analysis indicated that SR was 96.08% [95% CI: 93.10% to 98.21%] for the low-risk studies and 94.29% [95% CI: 90.01% to 97.36%] for the high risk studies (P < 0.438).

The age range of participants varied from 5 to over 60 years. Nonetheless, 93% (4,155 out of 4,479) of participants were 5 to 24 years old. Therefore, due to sparse data, it was impossible to perform a subgroup analysis across different age groups.

Of the 53 intervention groups, 42 groups comprised the general population, whereas the remaining 11 intervention groups comprised health care workers (HCWs). The subgroup analysis revealed that SR was 94.74% [95% CI: 91.75% to 97.11%] in the general population, whereas it was 96.83% [95% CI: 93.88% to 98.87%] among HCWs (P < 0.266).

For the primary vaccination, a recombinant

vaccine (RV) was used for 32 intervention groups, a plasma-derived vaccine (PDV) was used for 21 groups, and a mixed RV/PDV combination was used for 1 group. The subgroup analysis indicated that SR was 96.72% [95% CI: 94.10% to 98.59%] among RV recipients and 92.11% [95% CI: 86.41% to 96.27%] among PDV recipients (P < 0.104).

HB vaccine had been administered in a 3-dose schedule for 44 intervention groups, in a 4-dose schedule for 7 groups, and in a mixed schedule for the remaining 3 groups. However, the number of subgroups across strata was not enough to perform a subgroup analysis.

Most of the intervention groups (49 out of 53) had received a booster of RV, and 2 groups had received PDV. The type of booster was not specified in the remaining 2 groups; hence, there were not enough data to perform a subgroup-analysis across different types of booster. In addition, participants had received different booster doses for various types of RV, including Engerix-B, Recombivax HB, Genhevac B, Euvax B, and Hevac. Because the antigen contents of recombinant vaccines differ and the recommended vaccine doses vary across products from different manufacturers, assessing the doseresponse relationship across intervention groups was not reasonable.

We calculated the fold rise in geometric mean titer (GMT) from the baseline to assess the strength of the immune response to the booster in different strata. GMT rose 2,243-fold in Stratum 1, 284-fold in Stratum 2, 20-fold in Stratum 3, and 112-fold in Stratum 4. Furthermore, to determine the best time to measure GMT after the booster dose, we compared the results of 7 trials in which GMT was measured sequentially 3 times during the first, second, and fourth weeks after the booster dose. GMT increased 18-fold during the first week, reached 512-fold in the second week, and then decreased to 356-fold during the fourth week.

## Discussion

We found that the protective anti-HBs induced by initial vaccination waned over time, and thus the proportion of nonprotected vaccinees increased over time. Nonetheless, a considerable proportion of nonprotected participants who had lost anti-HBs over time responded vigorously to the booster dose. Therefore, according to these findings, the protection provided by a complete course of HB vaccine is dependent on immune memory rather than anti-HBs titer.

The observed dynamic of SR by strata is interesting and merits special attention because of its decreasing trend. The SR for HB vaccine was relatively high in the first 5 years after primary vaccination and decreased a little during the first decade. However SR decreased much more during the second decade and reached 85% 16 to 20 years after immunization. Therefore, attention should focus on this decreasing trend, which may indicate a certain fragility of the long-term immunity induced by HB vaccine. This raises the possibility of the need for a booster dose after the second decade, although revaccination does not seem necessary during the first or second decade after primary vaccination.

We developed a wide search strategy to encompass as many studies as possible. We screened 4,699 retrieved references and included 34 eligible studies involving 4,479 participants. Therefore, the amount of studies and the body of evidence identified allowed for a robust conclusion regarding the longterm seroprotection rate of HB vaccine. Although the number of actual participants may have been adequate in Stratum 4, the number of studies may not have been sufficient to confidently address the long-term protection provided by HB vaccine for as long as 16-20 years post initial vaccination. In addition, 93% of the participants aged 5 to 24 years and all of the participants in this review were apparently immunocompetent. Therefore, we cannot confidently generalize the results of this review to adults aged >25 years or to the immunocompromised

population.

We calculated the multiplicative rise in GMT from the baseline to assess the strength of the immune response to the booster in different strata. GMT rose 2,243-fold in Stratum 1, 284-fold in Stratum 2, 20-fold in Stratum 3, and 112-fold in Stratum 4. Furthermore, to determine the best time of measuring GMT post booster dose, we compared the results of 7 trials in which GMT was measured sequentially 3 times during the first, second, and fourth weeks after the booster dose. GMT increased 18-fold during the first week, reached 512-fold in the second week, and then decreased to 356-fold during the fourth week.

According to the results of this meta-analysis, GMT increased during the first and second weeks after booster injection and then decreased thereafter. Therefore, the best time for measuring immune response to a booster dose is at the end of second week after the administration of the booster.

Although the amount of included studies seems sufficient, the funnel plot was asymmetric. The methodological quality of the included studies differed, which itself may be an important potential source of funnel plot asymmetry. In addition, the heterogeneity in the results of the included studies may have also led to the funnel plot asymmetry in our review. Moreover, the exclusion of short-term booster studies (those with fewer than 5 years of follow-up) from our meta-analysis may have been another reason for funnel plot asymmetry.

There was evidence of heterogeneity (small P value and large I<sup>2</sup> statistic) among the results of the included studies. However, care must be taken in the interpretation of tests of heterogeneity. The importance of the observed value of I<sup>2</sup> depends on a) the magnitude and direction of the effects and b) the strength of evidence for heterogeneity (e.g., P value from the Chi<sup>2</sup> test) <sup>(63)</sup>. In addition, the Chi<sup>2</sup> test has low power when the sample size is small. Inversely, the statistic has high power in detecting a small amount of heterogeneity that may be clinically unimportant when there are many studies in a metaanalysis <sup>(63)</sup>, as was the case in our review. Therefore, we can attribute the observed heterogeneity to many studies being included in the meta-analysis as well as large sample sizes.

In this review, we revealed that the protection provided by HB vaccine is dependent on immune memory, rather than anti-HB titer, and furthermore that the seroprotection rate against HBV infection is sufficient in people who responded to a complete course of the vaccine. Thus, booster doses are unnecessary in immunocompetent persons for at least 20 years after primary vaccination. Our findings are confirmed by other reviews. For instance, one review revealed that protection was independent on antibody titer and indicated that following a complete course of vaccination, booster doses are unnecessary in immunocompetent persons (17). Another review found that immune response to the vaccine after 10 years was powerful in vaccinees whose antibody titer decreased to below the protective level <sup>(16)</sup>. A third review revealed that immune memory lasted for at least 15 years in immunocompetent individuals and emphasized that there are no data to support the need for booster doses of HB vaccine in immunocompetent individuals who have responded to a primary course (15). Finally, Mast et al. claimed that substantial evidence suggests that adults who respond to HB vaccination are protected from chronic HBV infection for at least 20 years, even if vaccinees lack detectable anti-HBs levels at the time of exposure <sup>(1)</sup>.

## **Conclusions**

We found that the protection provided by HB vaccine is dependent on immune memory rather than anti-HB titer; hence, recommendations for booster doses should be based on immune memory instead of persistence of the antibody. We also revealed that, following a full course of immunization, HB vaccine will induce a long-term and strong serologic immunity against HBV infection during the first and second decades after primary vaccination. However, SR decreased during the first decade and then decreased even faster in the second decade. This trend may indicate a degree of frailty in the longterm immunity induced by HB vaccine and raises the possibility of the need for a booster dose after the second decade. Still, universal revaccination does not seem necessary during the first and second decades after primary vaccination in healthy individuals with intact immune status who had fully responded to a complete course of the vaccine.

### Acknowledgements

We thank Dimitrinka Nikolova, Review Group Coordinator of the Cochrane Hepato-Biliary Group, who was involved in the formulation, supervision, and improvement of the protocol, as well as Sarah Louise Klingenberg and Kate Whitfield, Trials Search Coordinators of the Cochrane Hepato-Biliary Group, for designing the search strategies. We also thank Tahany Awad from Denmark and Joseph Luis Mathew from India, peer reviewers of the protocol, for their very worthwhile recommendations. We wish to acknowledge Christian Gluud, Coordinating Editor of the Cochrane Hepato-Biliary Group for editing the protocol. Finally, we thank Raheleh Kiashemshaki for translating the Chinese article.

This study was supported by the Department of Epidemiology and Biostatistics in the School of Public Health at Tehran University of Medical Sciences (TUMS), Tehran, Iran.

# References

- 1. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. *MMWR Recomm Rep.* 2006;**55**(RR-16):1-33; quiz CE1-4.
- McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142(5):333-41.
- Hepatitis B. World Health Organization. WHO/CDS/CSR/ LYO/20022:Hepatitis B; 2002.
- Dentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J. 2005;24(9):786-92.
- Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study. J Infect Dis. 1997;175(3):674-7.
- Liao SS, Li RC, Li H, et al. Long-term efficacy of plasmaderived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine. 1999;17(20-21):2661-6.
- Samandari T, Fiore AE, Negus S, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. *Pediatrics*. 2007;**120**(2):e373-81.
- van der Sande MA, Waight PA, Mendy M, et al. Longterm protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One. 2007;2(1):e753.
- Watson B, West DJ, Chilkatowsky A, Piercy S, Ioli VA. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. *Vaccine*. 2001;19(23-24):3164-8.
- Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315(4):209-14.
- Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ. 2002;325(7364):569.
- 12. John TJ, Cooksley G. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations? J Gastroenterol Hepatol. 2005;20(1):5-10.
- 13. Expanded program on immunization: Measles and Hepatitis B. World Health Organization. WHO/WPR/RC54/5; 2003.
- 14. Puro V, De Carli G, Cicalini S, *et al.* European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus. *Euro Surveill.* 2005;**10**(10):260-4.

- 15. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet. 2000;355(9203):561-5.
- 16. Fitzsimons D, Francois G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 2005;23(32):4158-66.
- 17. Banatvala JE, Van Damme P. Hepatitis B vaccine -- do we need boosters? *J Viral Hepat.* 2003;**10**(1):1-6.
- 18. Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. *Pediatr Infect Dis J.* 2003;22(2):157-63.
- Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. *Clin Gastroenterol Hepatol*. 2004;2(10):941-5.
- 20. Wang LY, Lin HH. Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago. *Vaccine*. 2007;25(41):7160-7.
- 21. Review Manager (RevMan) [Computer program]. RevMan. Version 5.0 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008.
- 22. Belloni C, Pistorio A, Tinelli C, et al. Early immunisation with hepatitis B vaccine: a five-year study. Vaccine. 2000;18(14):1307-11.
- 23. Da Villa G, Peluso F, Picciotto L, Bencivenga M, Elia S, Pelliccia MG. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. *Vaccine*. 1996;14(16):1503-5.
- 24. Dahifar H, Ghorbani A, Mousavi F. Anti-HBs in Immunized Children with Cuban Hepatitis B Vaccine and Impact of Booster Dose After five Years. *Pak J Med Sci.* 2008;24(4):571-4.
- 25. Gilca V, Serres G, Boulianne N, et al., editors. Antibody kinetics after vaccination with Engerix-B at the age of 8-10 years and the effect of a booster dose given five or ten years later. 8th Canadian Immunization Conference; 2008; Toronto.
- 26. Milne A, Krugman S, Waldon JA, et al. Hepatitis B vaccination in children: five year booster study. N Z Med J. 1992;105(940):336-8.
- 27. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 2004;23(7):650-5.
- 28. Duval B, Gilca V, Boulianne N, et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. *Pediatr Infect Dis J.* 2005;24(3):213-8.
- 29. Milne A, Waldon J. Recombinant DNA hepatitis B vaccination in teenagers: effect of a booster at 5 1/2 years. J Infect Dis. 1992;166(4):942.
- 30. Bucher B, Francioli P, Geudelin B, Fritzell B, Lavanchy D, Frei PC. Immunogenicity of a recombinant Pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster. *Eur J Clin Microbiol Infect Dis.* 1994;13(3):212-7.
- 31. Li H, Li RC, Liao SS, Yang JY, Zeng XJ, Wang SS. Persistence of hepatitis B vaccine immune protection and response to hepatitis B booster immunization. World J Gastroenterol. 1998;4(6):493-6.
- 32. Seto D, West DJ, Ioli VA. Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth. *Pediatr Infect Dis J.* 2002;**21**(8):793-5.
- 33. Floreani A, Baldo V, Cristofoletti M, et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine.

2004;22(5-6):607-10.

- 34. Trivello R, Chiaramonte M, Ngatchu T, et al. Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine. Vaccine. 1995;13(2):139-41.
- 35. Li X, Wu J, Liu J. [Seven-year follow-up in pupils immunized with hepatitis B vaccine and its revaccination]. *Zhonghua Yu Fang Yi Xue Za Zhi*. 1996;**30**(3):151-3.
- 36. Davidson M, Krugman S. Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose. J Infect. 1986;13 Suppl A:31-8.
- 37. Milne A, Hopkirk N, Moyes CD. Hepatitis B vaccination in children: persistence of immunity at 9 years. J Med Virol. 1994;44(2):113-4.
- 38. Williams JL, Christensen CJ, McMahon BJ, et al. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine. 2001;19(28-29):4081-5.
- 39. Saffar MJ, Rezai MS. Long-term antibody response and immunologic memory in children immunized with hepatitis B vaccine at birth. *Indian Pediatr.* 2004;**41**(12):1232-7.
- 40. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366(9494):1379-84.
- Chadha MS, Arankalle VA. Ten-year serological follow up of hepatitis B vaccine recipients. *Indian J Gastroenterol*. 2000;19(4):168-71.
- 42. Durlach R, Laugas S, Freuler CB, Rodriguez VE, Costa M. Ten-year persistence of antibody to hepatitis B surface antigen in healthcare workers vaccinated against hepatitis B virus, and response to booster vaccination. *Infect Control Hosp Epidemiol.* 2003;24(10):773-6.
- 43. Gabbuti A, Romano L, Blanc P, et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine. 2007;25(16):3129-32.
- 44. Xueliang W, Huiwen X, Guihua Z. Long-term efficacy and immunological memory of plasma-derived hepatitis B vaccine 11 years after initial inoculation. J Xi'an Med Univ, English Ed. 2000;12(2):122-5.
- 45. Lu CY, Ni YH, Chang LY, Lee CY, Chen DS, Huang LM. Long-term efficacy and immune memory of neonatal recombinant hepatitis B vaccination in adolescents aged 13-14 years. 13th International Congress on Infectious Diseases, Abstracts. Int J Infect Dis. 2008;12(Suppl. 1):e140.
- 46. Hammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine. 2007;25(39-40):6958-64.
- 47. Lu CY, Chiang BL, Chi WK, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. *Hepatology*. 2004;40(6):1415-20.
- 48. Lu CY, Ni YH, Chiang BL, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis. 2008;197(10):1419-26.
- 49. Su FH, Cheng SH, Li CY, *et al.* Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. *Vaccine*. 2007;**25**(47):8085-90.
- 50. Peces R, Laures AS. Persistence of immunologic memory in long-term hemodialysis patients and healthcare workers given hepatitis B vaccine: role of a booster dose on antibody

response. Nephron. 2001;89(2):172-6.

- 51. Ayerbe MC, Perez-Rivilla A. Assessment of long-term efficacy of hepatitis B vaccine. *Eur J Epidemiol.* 2001;**17**(2):150-6.
- 52. Boxall EH, J AS, El-Shuhkri N, Kelly DA. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis. 2004;190(7):1264-9.
- 53. Bryan JP, MacArthy P, Rudock A, et al. Hepatitis B vaccine booster dose: low-dose recombinant hepatitis B vaccines as a booster dose. Am J Infect Control. 1997;25(3):215-22.
- 54. Chan CY, Lee SD, Tsai YT, Lo KJ. Booster response to recombinant yeast-derived hepatitis B vaccine in vaccinees whose anti-HBs responses were initially elicited by a plasma-derived vaccine. *Vaccine*. 1991;9(10):765-7.
- 55. Coursaget P, Yvonnet B, Chotard J, *et al.* Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). *Lancet.* 1986;**2**(8516):1143-5.
- 56. Dahifar H, Mousavi F, Ghorbani A. Response of booster dose of Cuban Recombinant Hepatitis-B vaccine in nonresponder and hyporesponder children. *Pak J Med Sci.* 2007;23(1):23-6.
- 57. Laplanche A, Courouce AM, Benhamou E, Jungers P. Timing of hepatitis B revaccination in healthy adults. *Lancet.* 1987;1(8543):1206-7.

- 58. Lin HH, Liao HW, Lin SK, Wang LY. HLA and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. *Vaccine*. 2008;**26**(27-28):3414-20.
- 59. Shih HH, Chang MH, Hsu HY, Lee PI, Ni YH, Chen DS. Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan. *Pediatr Infect Dis J.* 1999;**18**(5):427-32.
- 60. Wismans PJ, van Hattum J, Mudde GC, Endeman HJ, Poel J, de Gast GC. Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. *J Hepatol.* 1989;8(2):236-40.
- 61. Zhang LX, Gu JB, Li P, Zhu CL. [Five-year follow-up and booster vaccination of blood derived hepatitis B vaccine for preventing HBV mother to baby transmission]. *Chinese J Clin Hepatol.* 1993;9(2):88-90.
- 62. Zhuang G, Xu H, Zuo H, Wang X, Liu P, Kong L. Sixyear efficacy of hepatitis B revaccination: A double-blind, placebo- controlled and randomized field trial. J Xi'an Med Univ, English Ed. 1998;10(1):44-8.
- 63. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration; 2008. Available from www.cochrane-handbook.org.